

7th February 2023

BSE Limited

1st Floor, New Trading Ring,
Rotunda Bldg, P.J. Towers,
Dalal Street,
Mumbai- 400 001.

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/Madam,

Sub.: Outcome of Board Meeting held on 7th February 2023

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e. 7th February 2023 inter alia transacted the following;

1. Un-audited Standalone and Consolidated Financial Results for the third quarter ended 31st December 2022 together with Limited Review Report.

The said Financial Results along with Limited Review Report are attached herewith.

2. The Board has recommended the reappointment of Mr. Yogesh B. Shah as an Executive Director for the period 3 (three) years subject to approval of Members.

The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 1.40 p.m.

We request to take the same on your record.

Thanking You,


Yours faithfully,

For Lyka Labs Limited

Kishore P. Shah

Company Secretary & Compliance Officer

Statement of Standalone Unaudited Financial Results for the Quarter / Nine Months Ended 31st December, 2022						
Particulars	(₹ in lakh)					
	Quarter Ended			Nine Months Ended		Year Ended
	31st December, 2022 (Unaudited)	30th September, 2022 (Unaudited)	31st December, 2021 (Unaudited)	31st December, 2022 (Unaudited)	31st December, 2021 (Unaudited)	31st March, 2022 (Audited)
I. Revenue						
Revenue from Operations	1,713.20	2,212.71	2,818.23	6,113.75	13,666.58	16,434.88
Other Income	111.39	103.90	67.29	283.68	205.98	271.98
II. Total Income	1,824.59	2,316.61	2,885.52	6,397.43	13,872.56	16,706.86
III. Expenses						
(a) Cost of Materials Consumed	506.87	581.64	590.97	1,772.35	2,065.76	2,693.80
(b) Purchase of Stock in trade	113.93	266.82	250.84	574.80	326.46	432.83
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(46.12)	14.84	46.37	(96.34)	(31.87)	(40.43)
(d) Employee benefits expense	430.37	449.99	382.21	1,251.20	1,197.18	1,621.96
(e) Finance Costs	304.18	291.45	459.50	875.69	1,701.19	1,992.13
(f) Depreciation and amortisation expense	332.53	345.50	211.80	1,019.39	625.74	1,538.87
(g) Other expenses	486.23	426.33	355.51	1,324.72	1,515.34	1,976.81
Total Expenses	2,127.99	2,376.57	2,297.20	6,721.81	7,399.80	10,215.97
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	(303.40)	(59.96)	588.32	(324.38)	6,472.76	6,490.89
V. Exceptional Items (Net)	689.68	13.72	(17.80)	703.48	186.52	466.83
VI. Profit / (Loss) before Tax	(993.08)	(73.68)	606.12	(1,027.86)	6,286.24	6,024.06
VII. Tax Expenses						
Current Tax	55.45	-	-	55.45	-	-
Deferred Tax	(27.20)	(34.04)	38.19	(55.18)	772.49	2,033.83
VIII. Net Profit / (Loss) after Tax	(1,021.33)	(39.64)	567.93	(1,028.13)	5,513.75	3,990.23
IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(3.18)	(3.18)	(3.82)	(9.53)	(16.46)	12.69
X. Total Comprehensive Income / (Loss)	(1,024.51)	(42.82)	564.11	(1,037.66)	5,497.29	4,002.92
Paid up Equity Share Capital (Face value ₹ 10/- each)	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity						1,574.85
XI. Basic and diluted earnings per share	(3.57)	(0.15)	1.97	(3.61)	19.19	13.87



Notes:


1. The above unaudited standalone financial results as reviewed by the Audit Committee at their meeting and have been approved and taken on record at the meeting of the Board of Directors held on 7th February 2023.
2. The Company operates in one reportable business segment i.e., "Pharmaceuticals".
3. The figures for the previous year / period have been regrouped / rearranged wherever considered necessary.
4. The Company will execute an agreement to sell land at Valsad for consideration of Rs. 525.00 Lakhs. Therefore, such land has been to be classified as held for sale. Assets classified as held for sale are measured at the lower of carrying amount and fair value less costs to sell at the time of re-classification. A total write down of Rs. 654.54 Lakhs was made during the quarter on account of such measurement for land.
5. Exceptional Items:

Sr. No.	Particulars	Quarter Ended 31 st December 2022
1	Loss on sale of Fixed Assets (non-operational)	29.07
2	Written off on account of reclassification of non-current assets	654.54
3	Other Written off	6.07
	Total	689.68

6. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited standalone financials results for the quarter ended 31st December 2022.

Mumbai
7th February 2023



For LYKA LABS LIMITED

Kunal N. Gandhi (DIN 01516156)
(Managing Director)



D. KOTHARY & CO.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Lyka Labs Limited (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34') prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Mehul N. Patel
Partner
Membership No. 132650




UDIN: 2313265086PXZU6153

Place: Mumbai
Date: February 7, 2023

Statement of Consolidated Unaudited Financial Results for the Quarter / Nine Months Ended 31st December, 2022

(₹ in lakh)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31st December, 2022 (Unaudited)	30th September, 2022 (Unaudited)	31st December, 2021 (Unaudited)	31st December, 2022 (Unaudited)	31st December, 2021 (Unaudited)	31st March, 2022 (Audited)
I. Revenue						
Revenue from Operations	1,781.56	2,552.66	3,557.36	7,083.42	15,889.98	19,408.49
Other Income	106.47	118.97	40.57	297.22	156.11	209.42
II. Total Income	1,888.03	2,671.63	3,597.93	7,380.64	16,046.09	19,617.91
III. Expenses						
(a) Cost of Materials Consumed	506.87	581.64	590.97	1,772.35	2,065.76	2,693.80
(b) Purchase of Stock in trade	137.90	502.86	769.15	1,285.54	2,001.25	2,644.56
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(46.21)	15.02	44.41	(96.44)	(33.08)	(41.04)
(d) Employee benefits expense	458.77	477.96	429.03	1,337.97	1,342.77	1,805.76
(e) Finance Costs	308.37	303.21	463.93	902.29	1,713.90	2,012.88
(f) Depreciation and amortisation expense	347.43	362.11	224.34	1,068.16	789.12	1,734.94
(g) Other expenses	502.84	472.33	421.88	1,429.56	1,658.53	2,190.43
Total Expenses	2,215.97	2,715.13	2,943.71	7,699.43	9,538.25	13,041.33
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	(327.94)	(43.50)	654.22	(318.79)	6,507.84	6,576.58
V. Exceptional Items (Net)	701.05	20.68	(17.79)	698.30	371.56	651.88
VI. Profit / (Loss) before Tax	(1,028.99)	(64.18)	672.01	(1,017.09)	6,136.28	5,924.70
VII. Non Controlling Interest	(10.57)	4.15	19.12	4.78	(63.56)	(55.65)
VIII. Profit / (Loss) before Tax	(1,018.42)	(68.33)	652.89	(1,021.87)	6,199.84	5,980.35
IX. Tax Expenses						
Current Tax / Earlier Year Tax	55.45	-	-	55.45	-	22.43
Deferred Tax	(32.28)	(29.95)	44.32	(56.88)	792.86	2,057.94
X. Net Profit / (Loss) after Tax	(1,041.59)	(38.38)	608.57	(1,020.44)	5,406.98	3,899.98
XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	0.54	(3.18)	(3.82)	(5.81)	(16.46)	14.01
XII. Total Comprehensive Income / (Loss)	(1,041.05)	(41.56)	604.75	(1,026.25)	5,390.52	3,913.99
XIII. Paid up Equity Share Capital (Face value Rs.10/- each)	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity						(1,535.15)
XIV. Basic and diluted earnings per share	(3.64)	(0.14)	2.11	(3.59)	18.83	13.57




Notes:

1. The above unaudited consolidated financial results as reviewed by the Audit Committee at their meeting and have been approved and taken on record at the meeting of the Board of Directors held 7th February 2023.
2. The Group operates in one reportable business segment i.e., "Pharmaceuticals".
3. The figures for the previous year / period have been regrouped / rearranged wherever considered necessary.
4. The Group will execute an agreement to sell land at Valsad for consideration of Rs. 525.00 Lakhs. Therefore, such land has been to be classified as held for sale. Assets classified as held for sale are measured at the lower of carrying amount and fair value less costs to sell at the time of re-classification. A total write down of Rs. 654.54 Lakhs was made during the quarter on account of such measurement for land.
5. Exceptional Items:


Sr. No.	Particulars	Quarter Ended 31 st December 2022
1	Loss on sale of Fixed Assets (non-operational)	29.07
2	Written off on account of reclassification of non-current assets	654.54
3	Other Written off	17.44
	Total	701.05

6. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited consolidated financial results for the quarter ended 31st December 2022.

Mumbai
7th February 2023



For LYKA LABS LIMITED


Kunal N. Gandhi (DIN 01516156)
(Managing Director)




Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Lyka Labs Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of following entities:
Subsidiaries
 - i) Lyka BDR International Limited
 - ii) Lyka Exports Limited
5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/information reflects total revenues of Rs. 104.12 lakhs and Rs. 1,375.03 lakhs, total net profit/(loss) after tax of Rs. (30.78) lakhs and Rs. 12.49 lakhs, total comprehensive income of Rs. (27.07) lakhs and Rs. 16.20 lakhs for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 respectively, which have been reviewed by us.






D. KOTHARY & CO.

Chartered Accountants

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W


Mehul N. Patel
Partner
Membership No. 132650



UDIN: 23132650 B6PXZY2339

Place: Mumbai
Date: February 7, 2023